Key Points Moderna's decision not to diversify outside of COVID has hurt its business substantially. The company is still generating COVID revenue, but it's insufficient to cover its operating expenses. It's working on a personalized cancer vaccine with Merck that's showing progress. 10 stocks we like better than Moderna › Can you believe that Moderna (NASDAQ: MRNA) was once worth more than $195 billion in 2021? Back then, the business looked on track to be the next big healthcare company. Then, ...